Galapagos is not a company lacking a vision—in fact, it has just made its second strategic announcement in six months. This one comes with a further pipeline trim and the loss of 200 roles.
https://www.fiercebiotech.com/biotech/galapagos-lays-200-staff-drops-kidney-and-fibrosis-programs-renewed-car-t-push